NEWS AND VIEWS FROM THE PHARMACEUTICAL FINE CHEMICAL AND CUSTOM MANUFACTURING SECTOR

Sunday 12 February 2012

Sales rise at Cambrex; looks to acquire

Cambrex reported a sales rise of almost 6% to $67.1m in Q4 2011, which the company attributed to increased demand for an API manufactured under a long-term supply agreement, a recently approved innovator product, higher sales of generic APIs, and higher volumes of controlled substances and products utilising its drug delivery technology. Cambrex CEO, Steven Klosk, said the company is looking to add further capabilities in generic finished products.
In-pharma Technologist

No comments: